Compounds > arginine

arginine and apixaban

arginine has been researched along with apixaban in 18 studies

Research

Studies (18)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	14 (77.78)	24.3611
2020's	4 (22.22)	2.80

Authors

Authors	Studies
Jiang, X; Wong, PC	1
Alban, S; Birschmann, I; Busse, J; Dittrich, M; Eller, T; Flieder, T; Knabbe, C	1
Cuker, A; Siegal, D	1
Arachchillage, DR; Baglin, T; Besser, M; Maclean, R; van Veen, JJ	1
Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI	1
Antman, EM; Giugliano, RP; Ruff, CT	1
Fanikos, J; Huisman, MV	2
Levy, JH	1
Kaatz, S; Milling, TJ	1
Bhagirath, VC; Eikelboom, JW; Monagle, S; Ng, KH	1
Gkiatas, I; Korompilias, AV; Kostas-Agnantis, I; Papadopoulos, DV; Tsantes, AG; Ziara, P	1
Fischer, AM; Godier, A; Martin, AC; Mauge, L; Smadja, DM	1
Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI	1
Chantarangkul, V; Clerici, M; Padovan, L; Peyvandi, F; Scalambrino, E; Tripodi, A	1
Singh Lubana, S; Singh, N; Tsai, HM	1
Ansell, J; Bakhru, S; Freedman, D; Laulicht, BE; Tracey, G; Villano, S	1
Austin Szwak, J; Cirbus, K; Simone, P	1

Reviews

11 review(s) available for arginine and apixaban

Article	Year
Monitoring and reversal of direct oral anticoagulants. Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Partial Thromboplastin Time; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombin Time	2015
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. American heart journal, 2016, Volume: 177 Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Atrial Fibrillation; Congresses as Topic; Dabigatran; Drug Monitoring; Factor Xa; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Piperazines; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Thrombin Time; Venous Thromboembolism	2016
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. Circulation, 2016, Jul-19, Volume: 134, Issue:3 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antithrombins; Arginine; Blood Coagulation Factors; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Plasma; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles	2016
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols. The American journal of medicine, 2016, Volume: 129, Issue:11S Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Clinical Protocols; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban	2016
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. The American journal of medicine, 2016, Volume: 129, Issue:11S Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Dabigatran; Deprescriptions; Emergencies; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Piperazines; Prothrombin Time; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative	2016
Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents. The American journal of medicine, 2016, Volume: 129, Issue:11S Topics: Animals; Antidotes; Arginine; Atrial Fibrillation; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thromboembolism	2016
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. The American journal of emergency medicine, 2016, Volume: 34, Issue:11S Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Clinical Protocols; Dabigatran; Emergency Treatment; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Patient Selection; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative; Thiazoles	2016
Clinical implications of reversal agents for direct oral anticoagulants. Future cardiology, 2017, Volume: 13, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism	2017
The role of new oral anticoagulants in orthopaedics: an update of recent evidence. European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2017, Volume: 27, Issue:5 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Tests; Dabigatran; Factor Xa; Hemorrhage; Humans; Orthopedic Procedures; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism	2017
[State of the art: Direct oral anticoagulants and transfusion]. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2017, Volume: 24, Issue:3 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Blood Transfusion; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thrombophilia	2017
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thrombosis and haemostasis, 2019, Volume: 119, Issue:1 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin	2019

Trials

1 trial(s) available for arginine and apixaban

Article	Year
Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects. European heart journal, 2022, Mar-07, Volume: 43, Issue:10 Topics: Administration, Oral; Adult; Aged; Anticoagulants; Arginine; Dabigatran; Healthy Volunteers; Humans; Middle Aged; Piperazines; Pyrazoles; Pyridones; Rivaroxaban	2022

Other Studies

6 other study(ies) available for arginine and apixaban

Article	Year
Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thrombosis and haemostasis, 2010, Volume: 104, Issue:2 Topics: Adenosine Diphosphate; Anticoagulants; Arginine; Azetidines; Benzimidazoles; Collagen; Dabigatran; Dose-Response Relationship, Drug; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Factor XIa; Humans; Morpholines; Pipecolic Acids; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Thromboplastin; Time Factors	2010
Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests. Clinical chemistry and laboratory medicine, 2014, Volume: 52, Issue:6 Topics: Anticoagulants; Arginine; Artifacts; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Fondaparinux; Humans; Morpholines; Pipecolic Acids; Platelet Function Tests; Point-of-Care Systems; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombelastography; Whole Blood Coagulation Time	2014
Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant. Thrombosis research, 2016, Volume: 143 Topics: Adult; Aged; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; Pipecolic Acids; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Sulfonamides; Venous Thrombosis	2016
Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban. Journal of thrombosis and thrombolysis, 2020, Volume: 49, Issue:3 Topics: Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Arginine; Hemophilia A; Humans; Partial Thromboplastin Time; Pipecolic Acids; Plasma; Pyrazoles; Pyridones; Sulfonamides	2020
Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia. The American journal of case reports, 2020, May-29, Volume: 21 Topics: Aged; Antithrombins; Arginine; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Pipecolic Acids; Pyrazoles; Pyridones; ST Elevation Myocardial Infarction; Sulfonamides; Thrombocytopenia; Thrombosis	2020
Rivaroxaban and apixaban for the treatment of suspected or confirmed heparin-induced thrombocytopenia. Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:1 Topics: Adult; Aged; Arginine; Factor Xa Inhibitors; Female; Heparin; Humans; Male; Middle Aged; Pipecolic Acids; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Sulfonamides; Thrombocytopenia	2022